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52 Poster Session-Iconducted a retrospective cohort study to describe the risk factors
and natural history of post-transplant DM and HTN. Consecutive
allogeneic HCT recipients from 2003–2005 were included in this
study if they had survived .1 year post-transplant and had not
received a previous HCT. DM and HTN were defined by published
adult and pediatric guidelines. The final cohort consisted of 180
patients (adult [$18 years] 106, pediatric [\18 years] 74); the median
age was 27 (range 0.2–69) years. Before HCT, 13% had DM, 9% had
HTN, 18% smoked and 19% were obese. Pediatric patients were
less likely to have pre-transplant DM, HTN, smoking history or
high-risk disease and more likely to receive myeloablative (MA)
conditioning. MA conditioning (Cy 1 1320 cGy TBI 6 Flu) was
given to 66% recipients, remainder received non-MA conditioning
(Cy 1 Flu 1 200 cGy TBI). All patients are followed until at least
2 years post-HCT at our center; among these 1 year survivors, 156
(87%) were alive at 2 years. Acute or chronic graft-versus-host dis-
ease occurred in 118 (66%) patients; of these, 34% received cyclo-
sporine (CSA) for .12 months and 47% received prednisone for
.12 months. Within 2-years after HCT, 54 (30%) had DM while
126 (70%) had HTN. Rates were similar for adult (DM 30%,
HTN 68%) and pediatric (DM 30%, HTN 73%) recipients. At 2
years post-HCT, 12% had persistent DM while 39% had persistent
HTN. Increasing cumulative dose of corticosteroids increased the
likelihood of having persistent DM at 2 years post-transplant (no ste-
roids 7%, # 0.25 mg/kg/d 13%, .0.25 mg/kg/d 27%, p 5 0.02);
such an association was not observed for HTN. On multivariate
analyses, risk factors for DM included history of DM pre-HCT (rel-
ative risk [RR] 5.0 [95% CI, 2.8–8.9]) and prednisone exposure (RR
2.4 [1.3–4.5]), while no predictive factors for resolution of post-
HCT DM were identified. CSA exposure was the only risk factor
for post-HCT HTN (RR 1.6 [1.1–2.5]), while history of HTN
pre-HCT was predictive for persistent HTN beyond 2 years (RR
3.07 [1.1–8.3]). DM and HTN are frequent among survivors of adult
and pediatric allogeneic HCT and can persist for an extended period
of time after transplantation. Continued monitoring and treatment
of DM and HTN is necessary in HCT survivors, especially if
survivors have been exposed to corticosteroids.135
MORTALITY OF HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS
ADMITTED TO A MEDICAL INTENSIVE CARE UNIT (MICU) AS PREDICTED
BY THE HEMATOPOIETIC CELL TRANSPLANTATION COMORBIDITY
INDEX (HCTCI)
Miller, S.M., Rossetti, J., Sahovic, E., Hilton, C., Lister, J. The Western
Pennsylvania Cancer Institute, Pittsburgh, PA
Introduction: Severity of illness scores validated in the critical
care setting are known to underestimate mortality in cancer patients.
We evaluated the Hematopoietic Cell Transplantation Comorbidity
Index (HCTCI) score (Sorror et al) as a predictor of mortality in
HCT recipients requiring intensive care.
Methods: A retrospective review of HCT recipients transplanted
between January 1, 1997, and March 1, 2007 was preformed. The
HCTCI score was calculated for each patient at the time of admis-
sion to the MICU. The primary endpoint was defined as survival
for seven days from the time of discharge from the MICU. Co-
variates analyzed included age, sex, conditioning regimen, need for
mechanical ventilation, use of vasopressors, time from transplant
to MICU admission, HCT type, and absolute neutrophil count
(ANC) at the time of MICU admission.
Results: Seventy-four of 892 patients (8.3%) required MICU
care. Forty-two (57%) were males, 32 (43%) females and the median
age was 47 (range: 22–71). Twenty-three (31%) patients received
autologous, 26 (35%) matched related donor (MRD) and 25 (34%)
matched unrelated donor (MUD) HCT. Overall mortality was
72%. Using the Wilcoxon signed-rank test, the HCTCI score was
found to be highly predictive of mortality (p\0.0001). None of the
patients with an HCTCI score of $10 survived. Univariate analysis
identified transplant type [mortality: autologous 52%, MRD 73%,
MUD 88%; p 5 0.02], conditioning [mortality: myeloablative
91% versus non-myeloablative 57%; p5 0.002], mechanical ventila-
tion (MV): [mortality: MV n5 43, 79% versus no MV n5 31, 61%;
p5 0.0003], and ANC [mortality:\500 /mL 88%, ANC$ 500 /mL
60%; p5 0.01] as correlating with mortality. In multivariate analysis
only the HCTCI score remained significantly correlated withmortality (p 5 0.001) with a point estimate of the odds ratio of 2.8
(95% C.I. 1.5–5.3).
Conclusion: This retrospective study demonstrates the predictive
value of the HCTCI for mortality when calculated on admission to
the MICU at our institution. The HCTCI score is easily calculated
and readily applicable in the clinical setting. Prospective study of
the HCTCI is needed for validation of this tool as a predictor of
mortality on MICU admission.136
UTILITY OF THE PSYCHOSOCIAL ASSESSMENT OF CANDIDATES FOR
TRANSPLANTATION (PACT) SCALE IN ALLOGENEIC BMT
Foster, L.W.1, McLellan, L.J.2, Rybicki, L.A.2, Bolwell, B.J.2 1Cleveland
State University, Cleveland, OH; 2Cleveland Clinic, Cleveland, OH
The Psychosocial Assessment of Candidates for Transplantation
(PACT) scale was completed on 120 allogeneic BMT patients pre-
transplant, from 11/2003 to 6/2007. The PACT has 8 items, each
rated on a 5-point scale, and an initial and final rating independently
based on the rater’s overall impressions of the candidate’s accepta-
bility for transplant. This study assessed utility of the PACT scale
for psychosocial screening in allogeneic BMT. Examined were asso-
ciations of the eight PACT subscales and the final rating with
medical outcomes, post-transplant. Significant relationships (P #
0.05) between PACT subscales and medical outcomes are as follows:
better scores on compliance with medications and medical advice as-
sociates with lower in-hospital mortality, shorter length of stay and
readmission duration, and faster neutrophil and platelet engraft-
ment; better scores on drug/alcohol use associates with faster platelet
engraftment; better scores on family/support system availability and
on relevant knowledge and receptiveness to education associates with
decreased risk of mortality. The final rating score and medical
outcomes are not significantly related; however, study findings
underscore the prognostic value of the PACT subscales and, thus,
utility for screening of BMT candidates.137
ETHICAL REASONING ABOUT PATIENT ELIGIBILITY IN ALLOGENEIC BMT
BASED ON PSYCHOSOCIAL CRITERIA
Foster, L.W.1, McLellan, L.J.2, Rybicki, L.A.2, Bolwell, B.J.2 1Cleveland
State University, Cleveland, OH; 2Cleveland Clinic, Cleveland, OH
Chairpersons of hospital ethics committees (HEC) and BMT
clinicians were compared regarding willingness to proceed with
allogeneic BMT given select psychosocial risk factors. A self- admin-
istered questionnaire was sent to 62 HEC chairpersons at hospitals
with an accredited BMT Program; response rate was 37%. Items in-
cluded background information, followed by six case vignettes from
a 2006 national survey on which BMT physicians, nurses, and social
workers agreed not to proceed with allogeneic BMT based on the fol-
lowing risk factors: suicidal ideation; use of addictive, illicit drugs;
history of non-compliance; has no caregiver; is alcoholic; and has
mild dementia. Opinions regarding transplant differed on one case
only, patient with mild dementia; 27% of HEC chairpersons recom-
mended not proceeding with BMT, which was significantly lower
than nurses (68%, p\ 0.001), physicians (63.5%, p\ 0.001), and
social workers (51.9%, P5 0.05). That HEC chairpersons disagreed
with BMT clinicians in the case of mild dementia may suggest that
they view dementia patients as more deserving of consideration for
BMT than patients who have some element of choice in the psycho-
social risk factor. In general, qualitative data reveal patterns of infor-
mal ethical reasoning that suggest transplant decisions may be linked
to patient responsibility for the psychosocial risk factor as well as
medical benefit/outcome.138
AVASCULAR NECROSIS (AVN) IN SURVIVORS OF HEMATOPOIETIC-
CELL TRANSPLANTATION (HCT): A LARGE SINGLE INSTITUTION
STUDY
McAvoy, S., Mulrooney, D.A., Arora, M., Baker, K.S., Burns, L.J.,
Majhail, N.S. University of Minnesota, Minneapolis, MN
AVN is a debilitating complication of HCT. We describe a con-
temporary cohort of patients with AVN after HCT to describe its
